Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

SomnoMed increases profitability in fiscal 2026, stock remains unmoved

SomnoMed reported revenue of AUD 114.5m (+3%) and EBITDA of AUD 10.9m (+19%) in fiscal 2026, with the EBITDA margin rising to 9.6%. Growth was supported by stronger margins, cost control and improved cash management, while a weaker second half in Europe and currency effects weighed on results. The share closed unchanged at $0.33, near its 52-week low. For 2027, management is targeting high single-digit revenue growth and expects stable EBITDA margins; drivers should include products such as Virtus and Rest Assure and the recruitment of additional dentists. » Altro su de.investing.com
SomnoMed increases revenue and EBITDA in H1 FY26, confirms full-year target

SomnoMed reports H1 FY26 revenue of 60.7 million AUD (+13%) and EBITDA of 7.8 million AUD (+35%) with an EBITDA margin of 13%. The FDA has granted RestAssure approval for compliance monitoring, and manufacturing capacity was expanded by more than 20%. The company confirms its full-year guidance of 119–126 million AUD revenue and 10–12 million AUD EBITDA, and plans a soft launch of RestAssure in FY27. Risks remain competition in APAC, macroeconomic pressure and regulatory implementation risks. » Altro su de.investing.com
SomnoMed increases H1 revenue by 13% and expands EBITDA margin

SomnoMed recorded a record first-half 2026 revenue of $60.7m (+13%) and EBITDA of $7.8m (+35%), lifting the EBITDA margin by 200 basis points to 13%. Growth was driven by Europe (+17%) and North America (+11%), while APAC declined by 4%. The company invested in expanding manufacturing (capex $3.4m) and received FDA clearance for the Rest Assure® technology; a soft launch in FY27 is being considered. SomnoMed reaffirmed its full-year guidance (revenue $119–126m, EBITDA $10–12m) despite negative free cash flow of -$0.9m. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, SOMNOMED LTD. ha registrato ricavi pari a 34,52M€ e un utile netto di 450,26k€

(EUR)	dic 2025	YoY
Ricavi	+34,52M	-
Utile lordo	+19,55M	-
Utile netto	+450,26k	-
EBITDA	+3,22M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+45,52M€
Numero di azioni	219,77M
Massimo/minimo a 52 settimane	+0,58€ - +0,20€
Dividendi	No
Beta	0,8
Rapporto P/E	−27,69
Rapporto PEG	−0,25
Rapporto P/B	+1,45
Rapporto P/S	+0,62

Profilo aziendale

SomnoMed Limited produziert und vertreibt zusammen mit seinen Tochtergesellschaften Geräte für die orale Behandlung von Schlafstörungen in Europa, Nordamerika und dem asiatisch-pazifischen Raum. Zu seinen Produkten gehören SomnoDent, ein orales Gerät zur Behandlung der obstruktiven Schlafapnoe, und SomnoBrux, ein Mundschutz zur Behandlung von Schäden durch Zähneknirschen, sowie SomTabs zur Reinigung seiner Geräte. Das Unternehmen wurde 1987 gegründet und hat seinen Sitz in Crows Nest, Australien.